15th June, 2021 4pm CET / 10am EST
What will this webinar address?
There is an emerging need for patient centric drug development. This webinar will define patient centricity and discuss its impact on the drug development cycle. We’ll review the current standard practices in drug development and identify the unmet needs in patient populations that result, with specific examples shared.
We’ll also discuss the emerging regulatory requirements and the implications for scientists and executives involved in drug development. Lastly, we’ll share some materials and technologies that can help you develop patient centric drug formulations with examples to illustrate how they can be utilized and their possible benefits.
When you attend this webinar, you will:
- Learn what constitutes a patient centric drug
- Understand the need and global markets that require patient centric doses
- Learn the process, benefits, and drawbacks to orphan and pediatric designations as specific examples of patient centric markets
- Understand how products get to market (regulatory and formulation considerations)
Donald Loveday, PhD
Global Business Development Manager
Dr. Donald Loveday joined SPI Pharma in January 2020 as the Global Business Development Manager, working closely with the global R&D team and responsible for the Pharmasolutions business area. Don’s experience includes Strategic Business Development, In/Out Licensing, technical innovation and P&L management. He has a strong global background in the pharmaceutical industry ranging from specialty excipients, API’s, biopolymers and gene-based fermentation technology used in the manufacture of novel drug actives. He has worked for Exxon Chemical, Dupont, Mycogenix, CSIRO Australia and Celanese in Texas. Don holds a B.S. in Chemical & Biomedical Engineering from the University of Tennessee, a PhD in Chemical Engineering from Virginia Tech and an MBA from Duke University.
Technical Development Manager, North America
Doug Hovey has been in the pharmaceutical industry for nearly 25 years with a proven track record highlighted by his direct involvement in six approved drug products. He has a diverse background with a strong knowledge in pharmaceutical sciences and understanding of the requirements needed for a successful regulatory filing and efficient manufacturing process. Doug has a broad base of experience in the areas of formulation development and technical service. He worked as a product development scientist for over 15 years before moving into a technical service and business development role within the pharmaceutical excipient industry. Doug is currently the Technical Development Manager in North America for SPI Pharma.
This webinar is brought to you by
Title: Trends and Advances in Patient Centric Drug Development
Date: 15th June, 2021
Time: 4pm CET / 10am EST
Duration: 60 minutes